TREATMENT OF RAYNAUD'S SYNDROME - CLINICAL UNITS 

NIH GUIDE, Volume 21, Number 4, January 31, 1992

 

RFP AVAILABLE:  NHLBI-HC-92-03

 

P.T. 34



Keywords:

  Cardiovascular Diseases 

  Clinical Trial 

  Biofeedback 

 

National Heart, Lung, and Blood Institute

 

The National Heart, Lung, and Blood Institute (NHLBI) requires six

clinical units to conduct a randomized clinical trial of

pharmacological and non-pharmacological treatments for Raynaud's

syndrome.  The primary goals of the study are to determine the best

therapies for primary Raynaud's syndrome, particularly regarding the

efficacy and duration of benefit from a course of temperature

biofeedback treatment.  Additionally, the study will evaluate the

efficacy of the biofeedback approach in pre-sclerodermal Raynaud's and

establish new information with respect to the role of emotional

reactivity in the onset of symptoms.  The study population for the

Raynaud's Treatment Study will consist of approximately 480 patients

recruited from six participating clinical units.

 

The period of performance is anticipated to begin September 30, 1992

through March 31, 1996.

 

The Request for Proposals (RFP) NHLBI-HC-92-03 will be available on or

about January 28, 1992, with proposals due April 17, 1992.  Six awards

are anticipated to be made during September 1992.  Written requests for

the RFP must include three mailing labels, self-addressed, and must

cite RFP No. NHLBI-HC-92-03.

 

Requests for copies of the RFP are to be sent to:

 

William M. Stevens

Contract Specialist for ECA Contracts Section

National Heart, Lung, and Blood Institute

Federal Building, Room 3C16

Bethesda, MD  20892

 

.

Return to 1992 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)